NIH RFA · NIAID · R61, R33

RFA-AI-28-024: Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Opens Jan 11, 2027Next due date: Feb 11, 2027Expires Feb 12, 2027

The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
RFA-AI-28-024
Type
RFA
Activity code
R61R33
Primary institute
NIAID · National Institute of Allergy and Infectious Diseases
Clinical trials
Not Allowed
Posted
Oct 13, 2026
Opens
Jan 11, 2027
Expires
Feb 12, 2027

RFA-AI-28-024 due dates

1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for RFA-AI-28-024
NewRenewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 11, 2027Not ApplicableNot ApplicableJuly 2027October 2027December 2027

Funded projects

NIH RePORTER lists no awards under RFA-AI-28-024 in FY2022–FY2026, and it is a new NOFO rather than a reissue. Awards usually appear a few months after the first review cycle.

Participating institutes

2 NIH institutes and offices take applications under RFA-AI-28-024. Contact the program officer at the institute that fits your research before applying.

  • NIAID · National Institute of Allergy and Infectious Diseases
  • none

Related notices

NIH lists no related notices for RFA-AI-28-024 yet.

Award terms

Application types allowed
New The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Budgets for the R61 phase are not expected to exceed 400,000 direct costs annually. Budgets for the R33 phase are not expected to exceed 750,000 direct costs annually.
Project period
Applicants may request up to 3 years of support for the R61 phase, and up to 2 years of support for the R33 phase. The maximum project period is 5 years total. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
NIAID intends to commit 4M in FY28 to fund 5-7 awards.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Other open NOFOs for R61, R33

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO

NIH grant searchLook up awards by topic, PI, or institution.Find funded PIsInvestigators with recent NIH awards in your research area.Institute fit by topicWhich NIH institutes and institutions lead a research area.Funding trendsYear-by-year NIH award totals for any keyword.